Provided by Tiger Trade Technology Pte. Ltd.

Estrella Immunopharma

0.7051
-0.0168-2.33%
Post-market: 0.70510.00000.00%17:52 EDT
Volume:44.28K
Turnover:31.34K
Market Cap:30.67M
PE:-2.82
High:0.7550
Open:0.7550
Low:0.6251
Close:0.7219
52wk High:3.15
52wk Low:0.6251
Shares:43.50M
Float Shares:14.57M
Volume Ratio:1.84
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2502
EPS(LYR):-0.3548
ROE:-268.50%
ROA:-251.86%
PB:-4.13
PE(LYR):-1.99

Loading ...

Company Profile

Company Name:
Estrella Immunopharma
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
- -
Office Location:
5858 Horton Street,Suite 370,EmeryVille,California,United States
Zip Code:
94608
Fax:
- -
Introduction:
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.

Directors

Name
Position
Cheng Liu
Chief Executive Officer and Director and President
Fan Wu
Independent Director
Hong Zhang
Chairperson of the Board and Director
Janelle Wu
Independent Director
Marsha Roberts
Independent Director
Pei Xu
Independent Director
Dengyao Jia
Director

Shareholders

Name
Position
Cheng Liu
Chief Executive Officer and Director and President
Peter Xu
Chief Financial Officer